表紙
市場調査レポート

尋常性乾癬 : パイプライン分析

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 199662
出版日 ページ情報 英文 334 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
尋常性乾癬 : パイプライン分析 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 334 Pages
概要

尋常性乾癬とは、慢性の、再発する、炎症性の皮膚疾患です。尋常性乾癬の頻度・重症度は喫煙、日光暴露、アルゴリズム、およびHIV感染といった環境的要因に影響されます。尋常性乾癬の症状には、銀色の鱗屑で覆われた皮膚の紅斑、小さな鱗屑、出血の可能性を伴う乾燥し砕けた皮膚、灼熱感、痒み、ヒリヒリする痛み、肥厚、爪のへこみまたは溝、関節腫脹、関節硬化、および頭皮のふけのような鱗屑などがあります。尋常性乾癬は主に皮膚科専門医の診察によって診断され、診断のための血液検査またはラボ検査はありません。

当レポートでは、尋常性乾癬に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

尋常性乾癬;概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

治療薬開発に従事している企業

  • 3SBio Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Avesthagen Limited
  • Avexxin AS
  • BIOCAD
  • Biocon Limited
  • Bionovis SA
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion, Inc.
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Forward Pharma A/S
  • Galectin Therapeutics, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Hetero Drugs Limited
  • Idera Pharmaceuticals, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Kineta, Inc.
  • 協和発酵キリン
  • LEO Pharma A/S
  • Lipidor AB
  • Mabion SA
  • Mabtech Limited
  • マルホ
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Promius Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • R-Tech Ueno, Ltd.
  • TetraLogic Pharmaceuticals
  • Therapeutic Proteins International, LLC
  • UCB S.A.
  • Valeant Pharmaceuticals International, Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (betamethasone dipropionate + calcipotriene)
  • (calcipotriene + betamethasone dipropionate)
  • (calcipotriene + betamethasone)
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • AM-001
  • AVX-001
  • betamethasone valerate + maxacalcitol
  • bimekizumab
  • bleselumab
  • brodalumab
  • calcipotriene
  • CC-90005
  • CT-327
  • dalazatide
  • DFD-01
  • DFD-06
  • dimethyl fumarate
  • DLX-105
  • DNX-114
  • DNX-514
  • DRM-02
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • GK-664S
  • GRMD-02
  • GSK-2981278
  • guselkumab
  • IDP-118
  • IDP-122
  • IMO-84001
  • IMP-731
  • infliximab biobetter
  • infliximab biosimilar
  • infliximab biosimilar
  • infliximab biosimilar
  • infliximab biosimilar
  • INV-103
  • KD-025
  • LEO-32731
  • LP-0113
  • M-7040
  • MOL-4239
  • MOL-4249
  • pefcalcitol
  • PF-04965842
  • PF-06700841
  • PH-10
  • piclidenoson
  • RTU-1096
  • SHP-141
  • tofacitinib
  • toreforant tartrate
  • UCB-5857
  • ustekinumab biosimilar

最新パイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7817IDB

Summary

Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
  • The report reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Plaque Psoriasis (Psoriasis Vulgaris) therapeutics and enlists all their major and minor projects
  • The report assesses Plaque Psoriasis (Psoriasis Vulgaris) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plaque Psoriasis (Psoriasis Vulgaris) Overview
  • Therapeutics Development
  • Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview
  • Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies
  • Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • AbGenomics International, Inc.
    • Almirall, S.A.
    • Amgen Inc.
    • AstraZeneca Plc
    • Avexxin AS
    • BIOCAD
    • Biocon Limited
    • Bionovis SA
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Can-Fite BioPharma Ltd.
    • Celgene Corporation
    • Cellceutix Corporation
    • Celltrion, Inc.
    • Clonz Biotech Private Limited
    • Coherus BioSciences, Inc.
    • Delenex Therapeutics AG
    • Eli Lilly and Company
    • Epirus Biopharmaceuticals, Inc.
    • Forward Pharma A/S
    • Galectin Therapeutics, Inc.
    • Genor BioPharma Co., Ltd.
    • GlaxoSmithKline Plc
    • Idera Pharmaceuticals, Inc.
    • Invion Limited
    • Johnson & Johnson
    • Kadmon Corporation, LLC
    • Kineta, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • LEO Pharma A/S
    • Lipidor AB
    • Mabion SA
    • Maruho Co., Ltd.
    • Mitsubishi Tanabe Pharma Corporation
    • Momenta Pharmaceuticals, Inc.
    • Mycenax Biotech Inc.
    • Novartis AG
    • Oncobiologics, Inc.
    • Pfizer Inc.
    • Promius Pharma, LLC
    • Protalix BioTherapeutics, Inc.
    • Provectus Biopharmaceuticals, Inc.
    • Sandoz International GmbH
    • Shanghai Celgen Bio-Pharmaceutical Co., Ltd.
    • Sucampo Pharmaceuticals, Inc.
    • Sun Pharma Advanced Research Company Ltd.
    • Takeda Pharmaceutical Company Limited
    • TetraLogic Pharmaceuticals
    • Therapeutic Proteins International, LLC
    • UCB S.A.
    • Valeant Pharmaceuticals International, Inc.
    • XBiotech USA, Inc.
    • Ziarco Pharma Ltd
  • Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (betamethasone dipropionate + calcipotriene) - Drug Profile
    • (betamethasone valerate + calcipotriene) - Drug Profile
    • (halobetasol propionate + tazarotene) - Drug Profile
    • AbGn-168H - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • AM-001 - Drug Profile
    • amiselimod hydrochloride - Drug Profile
    • AVX-001 - Drug Profile
    • baricitinib - Drug Profile
    • bimekizumab - Drug Profile
    • bleselumab - Drug Profile
    • BMS-986165 - Drug Profile
    • brodalumab - Drug Profile
    • BTX-1308 - Drug Profile
    • C-82 - Drug Profile
    • calcipotriene - Drug Profile
    • CC-90005 - Drug Profile
    • certolizumab pegol - Drug Profile
    • CJM-112 - Drug Profile
    • dalazatide - Drug Profile
    • DFD-01 - Drug Profile
    • DFD-06 - Drug Profile
    • dimethyl fumarate - Drug Profile
    • dimethyl fumarate - Drug Profile
    • DLX-105 - Drug Profile
    • DNX-114 - Drug Profile
    • etanercept - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • GK-664S - Drug Profile
    • GRMD-02 - Drug Profile
    • GSK-2831781 - Drug Profile
    • GSK-2981278 - Drug Profile
    • guselkumab - Drug Profile
    • IDP-122 - Drug Profile
    • IMO-8400 - Drug Profile
    • IMP-731 - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • INV-103 - Drug Profile
    • ixekizumab - Drug Profile
    • KD-025 - Drug Profile
    • KM-133 - Drug Profile
    • LEO-32731 - Drug Profile
    • LP-0113 - Drug Profile
    • M-7040 - Drug Profile
    • MC-201 - Drug Profile
    • namilumab - Drug Profile
    • pefcalcitol - Drug Profile
    • PF-06700841 - Drug Profile
    • PH-10 - Drug Profile
    • piclidenoson - Drug Profile
    • RA-18C3 - Drug Profile
    • remetinostat - Drug Profile
    • risankizumab - Drug Profile
    • RTU-1096 - Drug Profile
    • seletalisib - Drug Profile
    • tildrakizumab - Drug Profile
    • tofacitinib - Drug Profile
    • toreforant tartrate - Drug Profile
    • ustekinumab biosimilar - Drug Profile
    • ustekinumab biosimilar - Drug Profile
    • ustekinumab biosimilar - Drug Profile
    • ZPL-3893787 - Drug Profile
  • Plaque Psoriasis (Psoriasis Vulgaris) - Recent Pipeline Updates
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products
  • Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by 3SBio Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celgene Corporation, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Invion Limited, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kineta, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mabion SA, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech USA, Inc., H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H1 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top